CTGov Compliance My Organizations

Compliance Rate

Compliance Rate 100.0%

Compliant submissions 1

Incompliant submissions 0

Total trials 1

My Organizations' Clinical Trials

Showing 25 of 279 entries

View as:

Donor Natural Killer Cell Infusion, Rituximab, Aldesleukin, and Chemotherapy in Treating Patients With Relapsed Non-Hodgkin Lymphoma or Chronic Lymphocytic Leukemia

Phase: N/A Priority: Normal

NCT ID: NCT00625729 Org: User:

Start: 01/31/08 End: 04/30/10 Due: 04/30/11

T-Cell Depletion and Stem Cell Transplant for Immune Deficiencies and Histiocytic Disorders

Phase: N/A Priority: Normal

NCT ID: NCT00176826 Org: User:

Start: 09/30/00 End: 08/31/15 Due: 08/31/16

COMET2 Project 1 Filter Ventilation Study

Phase: N/A Priority: Normal

NCT ID: NCT03637972 Org: User:

Start: 10/18/18 End: 12/09/21 Due: 12/09/22

Post Transplant Donor Lymphocyte Infusion

Phase: N/A Priority: Normal

NCT ID: NCT00167180 Org: User:

Start: 01/31/04 End: 12/24/18 Due: 12/24/19

Carboplatin and Gemcitabine With Bevacizumab Every 2 Weeks for Stage IIIb/IV Non-small Cell Lung Cancer

Phase: N/A Priority: Normal

NCT ID: NCT00400803 Org: User:

Start: 03/31/07 End: 05/31/10 Due: 05/31/11

Infusion of Cell Populations From Unlicensed Umbilical Cord Blood Units

Phase: N/A Priority: Normal

NCT ID: NCT01451502 Org: User:

Start: 10/20/11 End: 12/31/25 Due: 12/31/26

Treg Cells for AGVHD in Non-myeloablative UCB Transplant

Phase: N/A Priority: Normal

NCT ID: NCT02118311 Org: User:

Start: 06/30/16 End: 09/30/18 Due: 09/30/19

Donor Umbilical Cord Blood Transplant in Treating Patients With Hematologic Cancer

Phase: N/A Priority: Normal

NCT ID: NCT00290628 Org: User:

Start: 10/31/99 End: 04/30/07 Due: 04/30/08

Relapse Prophylaxis With N-803 for AML and MDS Pts Following Allo HSCT

Phase: N/A Priority: Normal

NCT ID: NCT02989844 Org: User:

Start: 04/12/17 End: 08/31/22 Due: 08/31/23

Intraperitoneal Delivery of Adaptive Natural Killer (NK) Cells (FATE-NK100) With Intraperitoneal Int

Phase: N/A Priority: Normal

NCT ID: NCT03213964 Org: User:

Start: 10/19/17 End: 03/10/21 Due: 03/10/22

Hematopoietic Stem Cell Transplant for High Risk Hemoglobinopathies

Phase: N/A Priority: Normal

NCT ID: NCT02179359 Org: User:

Start: 09/02/14 End: 11/21/24 Due: 11/21/25

Neurotoxicity Prophylaxis With Intrathecal Dexamethasone and Simvastatin Post Axi-Cel

Phase: N/A Priority: Normal

NCT ID: NCT04514029 Org: User:

Start: 08/06/20 End: 12/31/25 Due: 12/31/26

Preservation of Ovarian Function After Hematopoietic Cell Transplant

Phase: N/A Priority: Normal

NCT ID: NCT01343368 Org: User:

Start: 07/31/11 End: 04/30/15 Due: 04/30/16

Metabolism of NNK in Japanese Americans

Phase: N/A Priority: Normal

NCT ID: NCT04228952 Org: User:

Start: 09/01/20 End: 12/31/24 Due: 12/31/25

Intraperitoneal FT536 in Recurrent Ovarian, Fallopian Tube, and Primary Peritoneal Cancer

Phase: N/A Priority: Normal

NCT ID: NCT06342986 Org: User:

Start: 07/11/24 End: 06/30/27 Due: 06/30/28

Erlotinib, Cisplatin, and Radiation Therapy in Treating Patients With Stage IB-Stage IVA Cervical Cancer

Phase: N/A Priority: Normal

NCT ID: NCT00428194 Org: User:

Start: 01/31/07 End: 03/31/08 Due: 03/31/09

Trial of Cell Based Therapy for DMD

Phase: N/A Priority: Normal

NCT ID: NCT06692426 Org: User:

Start: 03/20/25 End: 03/03/27 Due: 03/03/28

Allogeneic Natural Killer (NK) Cells in Patients With Advanced Metastatic Breast Cancer

Phase: N/A Priority: Normal

NCT ID: NCT00376805 Org: User:

Start: 04/30/06 End: 01/31/10 Due: 01/31/11

Clofarabine, Cyclophosphamide and Etoposide for Minimal Residual Disease Positive Acute Leukemia

Phase: N/A Priority: Normal

NCT ID: NCT01677949 Org: User:

Start: 12/31/13 End: 01/31/16 Due: 01/31/17

Umbilical Cord Blood Transplantation Using a Myeloablative Preparative Regimen for Hematological Diseases

Phase: N/A Priority: Normal

NCT ID: NCT01962636 Org: User:

Start: 12/31/16 End: 10/31/26 Due: 10/31/27

Diagnosis and Treatment of Periodontal Disease in Patients With AML

Phase: N/A Priority: Normal

NCT ID: NCT04530695 Org: User:

Start: 05/31/22 End: 11/30/26 Due: 11/30/27

Assessing the Time Demands of Cancer

Phase: N/A Priority: Normal

NCT ID: NCT05708703 Org: User:

Start: 11/13/23 End: 12/31/30 Due: 12/31/31

HSCT for High Risk Inherited Inborn Errors

Phase: N/A Priority: Normal

NCT ID: NCT00383448 Org: User:

Start: 09/30/06 End: 09/30/14 Due: 09/30/15

Allogeneic Natural Killer Cells in Patients With Recurrent Ovarian Cancer, Fallopian Tube, and Primary Peritoneal Cancer

Phase: N/A Priority: Normal

NCT ID: NCT00652899 Org: User:

Start: 03/31/08 End: 08/31/09 Due: 08/31/10

Adenovirus (RGDCRAdCOX2F)

Phase: N/A Priority: Normal

NCT ID: NCT06693986 Org: User:

Start: 12/27/24 End: 10/15/29 Due: 10/15/30

Title	NCT ID	Organization	User	Status	Start Date	End Date	Reporting Due Date	Last Checked	User Role	Org Created
Donor Natural Killer Cell Infusion, Rituximab, Aldesleukin, and Chemotherapy in Treating Patients With Relapsed Non-Hodgkin Lymphoma or Chronic Lymphocytic Leukemia	NCT00625729	Masonic Cancer Center, University of Minnesota	user2@example.com	None	2008-01-31	2010-04-30	2011-04-30	-	-	2025-07-14
T-Cell Depletion and Stem Cell Transplant for Immune Deficiencies and Histiocytic Disorders	NCT00176826	Masonic Cancer Center, University of Minnesota	user2@example.com	None	2000-09-30	2015-08-31	2016-08-31	-	-	2025-07-14
COMET2 Project 1 Filter Ventilation Study	NCT03637972	Masonic Cancer Center, University of Minnesota	user2@example.com	None	2018-10-18	2021-12-09	2022-12-09	-	-	2025-07-14
Post Transplant Donor Lymphocyte Infusion	NCT00167180	Masonic Cancer Center, University of Minnesota	user2@example.com	None	2004-01-31	2018-12-24	2019-12-24	-	-	2025-07-14
Carboplatin and Gemcitabine With Bevacizumab Every 2 Weeks for Stage IIIb/IV Non-small Cell Lung Cancer	NCT00400803	Masonic Cancer Center, University of Minnesota	user2@example.com	None	2007-03-31	2010-05-31	2011-05-31	-	-	2025-07-14
Infusion of Cell Populations From Unlicensed Umbilical Cord Blood Units	NCT01451502	Masonic Cancer Center, University of Minnesota	user2@example.com	None	2011-10-20	2025-12-31	2026-12-31	-	-	2025-07-14
Treg Cells for AGVHD in Non-myeloablative UCB Transplant	NCT02118311	Masonic Cancer Center, University of Minnesota	user2@example.com	None	2016-06-30	2018-09-30	2019-09-30	-	-	2025-07-14
Donor Umbilical Cord Blood Transplant in Treating Patients With Hematologic Cancer	NCT00290628	Masonic Cancer Center, University of Minnesota	user2@example.com	None	1999-10-31	2007-04-30	2008-04-30	-	-	2025-07-14
Relapse Prophylaxis With N-803 for AML and MDS Pts Following Allo HSCT	NCT02989844	Masonic Cancer Center, University of Minnesota	user2@example.com	None	2017-04-12	2022-08-31	2023-08-31	-	-	2025-07-14
Intraperitoneal Delivery of Adaptive Natural Killer (NK) Cells (FATE-NK100) With Intraperitoneal Int	NCT03213964	Masonic Cancer Center, University of Minnesota	user2@example.com	None	2017-10-19	2021-03-10	2022-03-10	-	-	2025-07-14
Hematopoietic Stem Cell Transplant for High Risk Hemoglobinopathies	NCT02179359	Masonic Cancer Center, University of Minnesota	user2@example.com	None	2014-09-02	2024-11-21	2025-11-21	-	-	2025-07-14
Neurotoxicity Prophylaxis With Intrathecal Dexamethasone and Simvastatin Post Axi-Cel	NCT04514029	Masonic Cancer Center, University of Minnesota	user2@example.com	None	2020-08-06	2025-12-31	2026-12-31	-	-	2025-07-14
Preservation of Ovarian Function After Hematopoietic Cell Transplant	NCT01343368	Masonic Cancer Center, University of Minnesota	user2@example.com	None	2011-07-31	2015-04-30	2016-04-30	-	-	2025-07-14
Metabolism of NNK in Japanese Americans	NCT04228952	Masonic Cancer Center, University of Minnesota	user2@example.com	None	2020-09-01	2024-12-31	2025-12-31	-	-	2025-07-14
Intraperitoneal FT536 in Recurrent Ovarian, Fallopian Tube, and Primary Peritoneal Cancer	NCT06342986	Masonic Cancer Center, University of Minnesota	user2@example.com	None	2024-07-11	2027-06-30	2028-06-30	-	-	2025-07-14
Erlotinib, Cisplatin, and Radiation Therapy in Treating Patients With Stage IB-Stage IVA Cervical Cancer	NCT00428194	Masonic Cancer Center, University of Minnesota	user2@example.com	None	2007-01-31	2008-03-31	2009-03-31	-	-	2025-07-14
Trial of Cell Based Therapy for DMD	NCT06692426	Masonic Cancer Center, University of Minnesota	user2@example.com	None	2025-03-20	2027-03-03	2028-03-03	-	-	2025-07-14
Allogeneic Natural Killer (NK) Cells in Patients With Advanced Metastatic Breast Cancer	NCT00376805	Masonic Cancer Center, University of Minnesota	user2@example.com	None	2006-04-30	2010-01-31	2011-01-31	-	-	2025-07-14
Clofarabine, Cyclophosphamide and Etoposide for Minimal Residual Disease Positive Acute Leukemia	NCT01677949	Masonic Cancer Center, University of Minnesota	user2@example.com	None	2013-12-31	2016-01-31	2017-01-31	-	-	2025-07-14
Umbilical Cord Blood Transplantation Using a Myeloablative Preparative Regimen for Hematological Diseases	NCT01962636	Masonic Cancer Center, University of Minnesota	user2@example.com	None	2016-12-31	2026-10-31	2027-10-31	-	-	2025-07-14
Diagnosis and Treatment of Periodontal Disease in Patients With AML	NCT04530695	Masonic Cancer Center, University of Minnesota	user2@example.com	None	2022-05-31	2026-11-30	2027-11-30	-	-	2025-07-14
Assessing the Time Demands of Cancer	NCT05708703	Masonic Cancer Center, University of Minnesota	user2@example.com	None	2023-11-13	2030-12-31	2031-12-31	-	-	2025-07-14
HSCT for High Risk Inherited Inborn Errors	NCT00383448	Masonic Cancer Center, University of Minnesota	user2@example.com	None	2006-09-30	2014-09-30	2015-09-30	-	-	2025-07-14
Allogeneic Natural Killer Cells in Patients With Recurrent Ovarian Cancer, Fallopian Tube, and Primary Peritoneal Cancer	NCT00652899	Masonic Cancer Center, University of Minnesota	user2@example.com	None	2008-03-31	2009-08-31	2010-08-31	-	-	2025-07-14
Adenovirus (RGDCRAdCOX2F)	NCT06693986	Masonic Cancer Center, University of Minnesota	user2@example.com	None	2024-12-27	2029-10-15	2030-10-15	-	-	2025-07-14

Compliance Rate

My Organizations' Clinical Trials

Appearance